A patient with esophageal squamous cell carcinoma who had a complete pathological response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil

被引：0

作者：

Takashi Ui

Michitaka Nagase

Yoshinori Hosoya

Kentaro Kurashina

Hidenori Haruta

Toru Zuiki

Yoshikazu Yasuda

Takashi Ura

Kei Muro

Hirofumi Fujii

机构：

[1] Jichi Medical University,Department of Surgery

[2] Jichi Medical University,Department of Clinical Oncology

[3] Aichi Cancer Center Hospital,Department of Clinical Oncology

来源：

Esophagus | 2011年 / 8卷

关键词：

Esophageal cancer; DCF; Preoperative chemotherapy; Docetaxel; Cisplatin;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

We report a case of a 51-year-old man with esophageal cancer who had a complete pathological response to preoperative chemotherapy with a combination of docetaxel, cisplatin and 5-fluorouracil (DCF). Endoscopy and esophagography showed a type II tumor 8 cm in diameter, located in the upper thoracic esophagus. On computed tomography the diagnosis was T3N1M0, stage III disease according to TNM classification. Before surgery, the patient received DCF therapy, consisting of docetaxel (60 mg/m2) on day 1, cisplatin (60 mg/m2) on day 1, and 5-fluorouracil (800 mg/m2) on days 1–5. The patient had grade 3 hematological toxicity, but two courses were administered as scheduled. After chemotherapy, esophagography and computed tomography showed that the tumor had shrunk. Esophagectomy with three-field lymph node dissection was performed. Histopathologically, an ulcer scar was found, with no residual cancer cells. There were no metastases in dissected lymph nodes. This regimen is considered to have a high potential.

引用

页码：59 / 62

页数：3

共 55 条

[1]

Ando N(2003)Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study—JCOG9204 J Clin Oncol 21 4592-4596

[2]

Iizuka T(2008)A randomized trial of postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus neoadjuvant chemotherapy for clinical stage II/III squamous cell carcinoma of the thoracic esophagus (JCOG 9907) J Clin Oncol (meeting abstracts) 26 4510-1704

[3]

Ide H(2007)Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer N Engl J Med 357 1695-1715

[4]

Ishida K(2007)Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer N Engl J Med 357 1705-4997

[5]

Shinoda M(2006)Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group J Clin Oncol 24 4991-125

[6]

Nishimaki T(2004)Guidelines for clinical and pathologic studies on carcinoma of the esophagus, ninth edition Esophagus 61–88 107-7

[7]

Igaki H(2005)Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT) Ann Surg. 241 810-9

[8]

Kato H(1995)Lymph node dissection for thoracic esophageal carcinoma. Two- and 3-field lymph node dissection Ann Chir Gynaecol 84 193-22

[9]

Ando N(2002)Phase I trial of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) Esophagus 7 7-226

[10]

Shinoda M(2004)A case of esophageal cancer with multiple lymph node metastases which responded to neoadjuvant chemotherapy (DCF therapy) Br J Cancer 90 348-undefined

← 1 2 3 4 5 6 →